Table 5.
Exposure-adjusted patient rates of cardio- and cerebrovascular disorder events during the OLTP.
| Erenumab 70 mg (n = 383) n (r) | Erenumab 140 mg (n = 250) n (r) | Erenumab 70/140 mg (n = 383) n (r) | |
|---|---|---|---|
| Cardiovascular adverse events | 2 (0.3) | 0 (0.0) | 2 (0.2) |
| Ischemic heart disease | 2 (0.3) | 0 (0.0) | 2 (0.2) |
| Cardiac disorders | 1 (0.1) | 0 (0.0) | 1 (0.1) |
| Myocardial ischemia | 1 (0.1) | 0 (0.0) | 1 (0.1) |
| Investigations | 1 (0.1) | 0 (0.0) | 1 (0.1) |
| Blood creatine phosphokinase MB increased | 1 (0.1) | 0 (0.0) | 1 (0.1) |
| Cerebrovascular adverse events | 0 (0.0) | 0 (0.0) | 0 (0.0) |
n: number of patients reporting at least one occurrence of event; r: exposure-adjusted rate per 100 patient-years.
Note: Table based on the following search criteria: Ischemic central nervous system vascular conditions SMQ (narrow), ischemic heart disease SMQ (narrow) and peripheral arterial disease (PAD) AMQ (narrow). Coded using MedDRA version 20.0.